1-3 of 3
Vivian J. M. Cline
Close
Sort by
Journal Articles

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Clinical Trials & Observations
Jonathan W. Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Christopher A. Yasenchak
Journal: Blood
Blood (2024) 143 (9): 786–795.
https://doi.org/10.1182/blood.2022019536
Published: 2024
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Shweta Jain, Jingmin Liu, Joseph Thaddeus Beck
Journal: Blood
Blood (2023) 142 (Supplement 1): 4435.
https://doi.org/10.1182/blood-2023-190260
Published: 2023
Journal Articles

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Clinical Trials & Observations
Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo E. Bordoni, Vivian J. M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang, Christopher A. Yasenchak
Journal: Blood
Blood (2017) 130 (26): 2829–2837.
https://doi.org/10.1182/blood-2017-06-787200
Published: 2017
Includes: Supplemental data